CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Cardiol Therapeutics Inc.
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 40-F on Mar 31, 2026
$1.10+0.00 (0.00%)
Close on Oct 19, 2026
Margins need revenue and profit figures
This company does not report the lines needed to calculate margins.
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|
Returns and balance sheet
7 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2019 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Current ratio | – | 5.94 | 4.16 | |
| Diluted shares | – | 30M | 87M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Cardiol Therapeutics generated C$124.86M from operations and spent C$197.71K on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
C$124.86M
Used
C$197.71K
Capital expenditureC$197.71K100%DividendsC$00%Share buybacksC$00%
DuPont needs revenue, assets and equity
This company does not report all three for consecutive years.
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
0of 3 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero–
- Cash generatingOperating cash flow above zero-C$23.85M
- Return on assets improvedROA up on the prior year– → –
- Earnings backed by cashOperating cash flow above net income-C$23.85M vs –
- Less leverageLong-term debt to assets fell– → –
- Better liquidityCurrent ratio rose4.52 → 4.16
- No dilutionShare count did not rise72M → 87M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose– → –